Arkolith/Insider Trading/OKYO/Form 4

Shah Keeren Rameshchandra

Chief Financial OfficerOKYO Pharma Ltd (OKYO) · full profile →Form 4 · filed Jun 10, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 8, 2026Grant(A)40K$1.85$74K545K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-26-028131) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML